Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 19/20 | 0.77 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3702185 | 0.97 | ADORA1 (0.76) | ADORA1SLC6A3 | |
| Diethanolamine SCHEMBL3690654 | 0.95 | ADORA1 (0.76) | ADORA1SLC6A3KDM4EMEN1ALDH1A1 | |
| Diethanolamine SCHEMBL3690141 | 0.93 | ADORA1 (0.74) | ADORA1SLC6A3KDM4EMEN1ALDH1A1 | |
| SCHEMBL7642574 | 0.90 | ADORA1 (0.78) | ADORA1SLC6A3KDM4EMEN1ALDH1A1 | |
| SCHEMBL3703461 | 0.89 | ADORA1 (0.74) | ADORA1SLC6A3KDM4EMEN1ALDH1A1 | |
| SCHEMBL3699454 | 0.88 | ADORA1 (0.81) | ADORA1SLC6A3KDM4EMEN1ALDH1A1 | |
| SCHEMBL13938233 | 0.88 | ADORA1 (0.79) | ADORA1SLC6A3KDM4EMEN1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL3698557 | 0.88 | ADORA1 (0.79) | ADORA1SLC6A3KDM4EMEN1ALDH1A1 | |
| Capadenoson SCHEMBL174016 | 0.87 | ADORA1 (1.00) | ADORA1SLC6A3 | |
| SCHEMBL1177362 | 0.87 | ADORA1 (0.81) | ADORA1SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122820-A1 | PRODRUGS AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122820-A1 | PRODRUGS AND THE USE THEREOF | TPMT, DPP4, PYGL | ADORA1 1087/4885SLC6A3 825/4885KDM4E 987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.